Christian Rohlff

CEO at Oxford BioTherapeutics

Speaker

Christian has served as CEO of Oxford BioTherapeutics (“OBT”) since founding the company and acquiring its core technology, OGAP®-Verify. He brings more than 30 years of international experience in oncology drug discovery, platform driven target identification, and strategic partnering. He has a proven track record of building and scaling oncology businesses from discovery through clinical development, creating value through high quality pharmaceutical partnerships and capital efficient growth.

Christian founded and built OBT into a leading oncology company specialising in proteomics driven target discovery for antibody-based therapeutics. He established OGAP®-Verify, the world’s largest oncology focused proteomics platform, enabling the systematic discovery and validation of novel cancer targets. Under his leadership, OBT has evolved from a discovery start up into a partner validated, clinical stage oncology company with expanding preclinical and development capabilities. He has also led the establishment of multiple strategic collaborations with leading pharmaceutical companies, including Bristol Myers Squibb, Roche, GSK, Boehringer Ingelheim, and ImmunoGen, spanning ADCs, T-cell engagers, and antibody platforms.